|Articles|November 20, 2017

EMA to Relocate to Amsterdam, The Netherlands

The long waited news of where the EMA will be relocated to due to the United Kingdom’s decision to withdraw from the EU has finally been revealed today. The European Medicines Agency will relocate to Amsterdam in the Netherlands just in time for the move in March of 2019.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor,Joseph Kim,Lauren Briggs

August 12th 2026

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

© photon_photo - © photon_photo - stock.adobe.com

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ByMario Alejandro Castellanos Urdaibay, MD, MSc

August 11th 2026

Breaking the Efficacy Ceiling in IBD and Beyond

ByMichael Christel,Kori Wallace, MD, PhD

August 11th 2026

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

ByAndy Studna, Senior Editor

August 11th 2026

EMA to Relocate to Amsterdam, The Netherlands

Related Content

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Trending on Applied Clinical Trials Online

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma